July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Repeatability and Sensitivity Validation of an ipad based Visual Acuity Application
Author Affiliations & Notes
  • Michel Guillon
    Ocular Technology Group International, London, ENGLAND, United Kingdom
    School of Heath Sciences, Aston University, Birmingham, United Kingdom
  • Pasquale Pepe
    Ocular Technology Group International, London, ENGLAND, United Kingdom
  • Kishan Patel
    Ocular Technology Group International, London, ENGLAND, United Kingdom
  • Ruchi Gupta
    Ocular Technology Group International, London, ENGLAND, United Kingdom
  • Trisha Patel
    Ocular Technology Group International, London, ENGLAND, United Kingdom
  • Footnotes
    Commercial Relationships   Michel Guillon, Aston University (C), Ocular Technology Group International (E), Ocular Technology Group International (F); Pasquale Pepe, Ocular Technology Group International (E); Kishan Patel, Ocular Technology Group International (F); Ruchi Gupta, Ocular Technology Group International (E); Trisha Patel, Ocular Technology Group International (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5910. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michel Guillon, Pasquale Pepe, Kishan Patel, Ruchi Gupta, Trisha Patel; Repeatability and Sensitivity Validation of an ipad based Visual Acuity Application. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5910.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Visual acuity (VA) is the FDA standard measurement to quantify vision clarity and the ETDRS is the approved gold standard. OTG-i Vision Suite (OVS), an iPad application driving a standard 4K screen that measures VA more comprehensively than the ETDRS has been developed for use in multisites regulatory clinical study. The objective of this study was to validate the application repeatability and sensitivity with the presence of defocus for non-presbyopic and presbyopic populations.

Methods : Three charts were evaluated: OVS letters (10 ISO letter per line) (LVA) and individual Landolt C (20 rings per line, each displayed for 300ms) (TCVA) against the ETDRS chart as control. All the charts were presented under controlled luminance (≥160cd/m2) representative of daytime lighting at 90% contrast. Repeatability (mean difference & 95% CI) was established by comparing the measurements carried out a few days apart with the participants optimal vision correction. Sensitivity (mean VA change from optimal) was measured by quantifying the vision loss associated with +0.25D and +0.50D defocus. The validation was carried out on non-presbyopic (18-39 years, n=19) and presbyopic (40-60 years, n=15) populations.

Results : Repeatability: excellent for all three charts with a 95% CI less than 0.1logMAR in all cases and a trend towards a smaller 95% CI for LVA and TCVA than ETDRS [mean (CI)] logMAR. For 18-39yrs: LVA 0.029 (0.059); TCVA 0.041 (0.064); ETDRS 0.036 (0.078). For 40-60yrs: LVA 0.047 (0.039); TCVA 0.008 (0.065); ETDRS 0.008 (0.090)]. Sensitivity: i. Overall all three tests detected a significant change in VA (p<0.05) with both defocus and had similar magnitude of mean logMAR VA loss (+0.25D: 0.052 to 0.067; +0.50D: 0.114 to 0.137); ii. For each population group, LVA and TCVA detected a significant change for both defocus (p<0.05) but the ETDRS failed to detect a difference for the 18-39yrs with +0.25D defocus (p=0.094).

Conclusions : The results showed that all three charts evaluated achieved high repeatability and sensitivity to detect defocus with a trend for the OVS to be more sensitive to detect slight defocus in non-presbyopic population than the ETDRS. Additionally, the TCVA demonstrated similar repeatability as the ETDRS, supporting the clinical suitability of the exposure time selected.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×